SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-024753
Filing Date
2023-02-23
Accepted
2023-02-23 16:05:44
Documents
12
Period of Report
2023-02-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm237397d1_8k.htm   iXBRL 8-K 27191
  Complete submission text file 0001104659-23-024753.txt   201638

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA sls-20230223.xsd EX-101.SCH 3060
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE sls-20230223_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sls-20230223_pre.xml EX-101.PRE 22614
6 EXTRACTED XBRL INSTANCE DOCUMENT tm237397d1_8k_htm.xml XML 3610
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33958 | Film No.: 23659583
SIC: 2834 Pharmaceutical Preparations